Electroporation-mediated intravascular delivery

• US 5,944,710 A
• Filed: 06/24/1996
• Issued: 08/31/1999
• Est. Priority Date: 06/24/1996
• Status: Expired due to Fees

• Current Assignee: Genetronics, Inc. (Inovio Pharmaceuticals, Inc.)
• Original Assignee: Genetronics, Inc. (Inovio Pharmaceuticals, Inc.)
• Inventors: Dev, Nagendu B., Hofmann, Gunter A., Dev, Sukhendu B.
• Primary Examiner(s): Bockelman, Mark
• Application Number:
  US08/668,725
• Time in Patent Office: 1,163 Days
• Field of Search: 604/19-21, 604/49, 604/500, 435/173.6, 935/52
• US Class Current: 604/500
• CPC Class Codes: A61N 1/306 Arrangements where at least part of the apparatus is introduced into the body
• CPC Class Codes: A61N 1/325 for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body electrodes for external use A61N1/0428
• CPC Class Codes: A61N 1/327 for enhancing the absorption properties of tissue, e.g. by electroporation
• CPC Class Codes: Y10S 977/906 Drug delivery

Abstract

A method for sustained intravascular delivery via electroporation is provided. The method is useful for delivery of therapeutic compositions such as antithrombotic and anticoagulant agents. The invention also provides a catheter apparatus for introducing a composition into at least one cell in a vessel in a subject.

Claims

1. A method for sustained intravascular delivery of a composition to cells of a vessel in a subject, the method comprising:

denuding the endothelial lining of a vessel,

administering the composition locally to the vessel in the subject;

applying an electrical impulse directly to cells of the vessel via electroporation by directly contacting the vessel with electrodes, wherein the impulse is of sufficient strength and time for the impulse to cause electroporation of at least one cell in the interior of the vessel such that the composition is delivered into the vessel and is retained in the vessel for sustained, localized delivery.

2. The method of claim 1, wherein the composition is selected from the group consisting of an antithrombotic, antirestenoitic, antiplatelet, platelet receptor and mediator inhibitor, growth factor inhibitor, antibody, antiinflammatory and antiproliferative composition.

3. The method of claim 1, wherein the composition is selected from the group consisting of heparin, hirulog, tPA, urokinase, streptokinase, cyclosporin, antistatin, and warfarin.

4. The method of claim 1, wherein the electrical impulse applied is from approximately 50 to 90 volts.

5. The method of claim 1, wherein the electrical impulse applied has a duration of about 100 μ

s to 100 ms.

6. The method of claim 5, wherein the electrical impulse applied has a duration of from about 100 μ

s to 1000 μ

s.

7. The method of claim 1, wherein the administering of the composition and the application of the electrical impulse are substantially contemporaneous.

8. The method of claim 1, wherein application of the electrical impulse is via a catheter apparatus.

9. The method of claim 1, wherein the electrical impulse(s) is selected from the group consisting of square wave pulses, exponential waves, unipolar oscillating wave forms of limited duration, bipolar oscillating wave forms of limited duration, and other wave forms generating electric fields.

10. The method of claim 1, wherein the electrical impulse has a pulsing frequency of about 1 to 100 Hz.

11. The method of claim 1, wherein from about 1 to 10 electrical pulses are applied.

12. The method of claim 1, further comprising using iontophoresis for delivery of the composition to the cell.

13. The method of claim 1, wherein the vessel is a blood vessel.

14. The method of claim 1, wherein said cell in the interior of the vessel is in the adventitial region of the vessel.

16. The method of claim 1, wherein said cell in the interior of the vessel is in the medial region of the vessel.

17. The method of claim 1 or claim 15, wherein the composition is a polynucleotide.

18. The method of claim 17, wherein the polynucleotide encodes a polypeptide selected from the group consisting of Vascular endothelial growth factor (VEGF), endothelial specific mitogen, platelet derived growth factor, fibroblast growth factor, and interferon.

15. A method for sustained intravascular delivery of a composition to cells of a vessel in a subject, the method comprising:

denuding the endothelial lining of a vessel

administering the composition to the vessel of a subject using an apparatus having;

a catheter having at least one inflatable balloon portion;

at least one infusion passage for introducing the composition into the subject;

a first electrode positioned adjacent to at least one infusion passage;

a second electrode positioned with respect to the first electrode and the subject such that an electric field sufficient to cause electroporation of at least one cell in the vessel is generated, thereby allowing the composition to enter at least one cell after introduction of the composition through at least one infusion passage;

applying an electrical impulse to cells of a vessel in the subject via electroporation, wherein the electrodes are in the vessel and wherein the impulse is of sufficient strength and time for the impulse to cause electroporation of at least one cell in the interior of the vessel such that the composition is delivered locally into the vessel and is retained in the vessel for sustained delivery.